title: A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy.
abstract: OBJECTIVE
  To compare the complication rates of Hickman lines and Port-a-Caths in patients undergoing infusional chemotherapy for solid tumours.
  
  
  METHODS
  A single institution retrospective analysis comparing complication rates for 30 Hickman lines and 33 Port-a-Caths inserted for chemotherapy in adults with solid tumours was carried out.
  
  
  RESULTS
  Patients were well matched in terms of primary site and chemotherapy regimen. In both cases, over 85% were inserted radiologically under local anaesthetic. The total time in situ for Hickman lines and Port-a-Caths was 3539 days (median 83, range 6-585) and 5783 days (median 158, range 20-456), respectively. The complication rate for Hickman lines was 5.09/1000 catheter days, almost five times that for Port-a-Caths, with 1.04/1000 catheter days, a relative risk of 4.9 (confidence interval: 1.9-15.1, P=0.0003). Most (73%) complications occurred within 4 weeks of insertion. However, some arose much later: the range of time to complication was 1-304 days for Hickman lines and 1-132 days for Port-a-Caths. Infection was the most common complication, accounting for nine of 18 Hickman line complications and five of six Port-a-Cath complications, giving an overall infection rate of 2.54/1000 catheter days and 0.86/1000 catheter days, respectively. Additionally, Hickman lines had a 26% leakage rate or displacement rate, which did not occur at all in the Port-a-Cath group. Complications required the removal of 16 Hickman lines and five Port-a-Caths. The rate of removal was five times higher for Hickman lines (Hickman lines=4.52/1000 catheter days, Port-a-Caths=0.86/1000 catheter days, P=0.0027). Overall, the cost of Port-a-Caths was less than that of Hickman lines.
  
  
  CONCLUSIONS
  In this study, Port-a-Caths were shown to be both safer and cheaper than Hickman lines for patients requiring infusional chemotherapy.
authors.affiliation: Academic Department of Oncology, Royal Free and University College Medical School, Rowland Hill Street, London, UK.
authors.forename: F
authors.initials: F
authors.lastname: Ng
authors.forename: H
authors.initials: H
authors.lastname: Mastoroudes
authors.forename: E
authors.initials: E
authors.lastname: Paul
authors.forename: N
authors.initials: N
authors.lastname: Davies
authors.forename: J
authors.initials: J
authors.lastname: Tibballs
authors.forename: D
authors.initials: D
authors.lastname: Hochhauser
authors.forename: A
authors.initials: A
authors.lastname: Mayer
authors.forename: R
authors.initials: R
authors.lastname: Begent
authors.forename: T
authors.initials: T
authors.lastname: Meyer
mesh_terms: D000553:Ambulatory Care; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000209:etiology; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000191:economics; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000191:economics; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents